Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 25.04

+2.6%

Nov 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sonki who wrote (1282)	1/8/1999 11:11:00 AM
From: Anthony Wong	Read Replies (2) of 1722

Wellpoint, Others Limit Coverage of Celebrex, Times Reports Bloomberg News January 8, 1999, 9:54 a.m. ET St. Louis, Jan. 8 (Bloomberg) -- Wellpoint Health Networks Inc., Aetna U.S. Healthcare and other U.S. health-care companies and insurers plan to limit coverage of Monsanto Co.'s newly approved Celebrex arthritis drug, possibly because of its price, the New York Times reported. Wellpoint and Aetna have restricted use of the drug, while United Healthcare Corp. has given the drug the lowest reimbursement it offers. Officials at Wellpoint and Kaiser Permanente Group, which is considering not covering the drug, said Celebrex is much more expensive than generic brands, the paper said. Monsanto, a leading agricultural-products company expanding into pharmaceuticals, said last month it will sell Celebrex arthritis drug at prices as low as or lower than comparable brand- name painkillers. (New York Times 1/8 C18 www.nytimes.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next